See more : Wesdome Gold Mines Ltd. (RKVA.F) Income Statement Analysis – Financial Results
Complete financial analysis of DiaMedica Therapeutics Inc. (DMAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DiaMedica Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Towngas Smart Energy Company Limited (1083.HK) Income Statement Analysis – Financial Results
- Korea Airport Service Co.,Ltd. (005430.KS) Income Statement Analysis – Financial Results
- Pruksa Holding Public Company Limited (2PR4.SG) Income Statement Analysis – Financial Results
- PT Dwi Guna Laksana Tbk (DWGL.JK) Income Statement Analysis – Financial Results
- BCE Inc. (BECEF) Income Statement Analysis – Financial Results
DiaMedica Therapeutics Inc. (DMAC)
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 160.62K | 25.74K | 25.68K | 33.88K |
| Cost of Revenue | 30.00K | 25.00K | 24.00K | 21.00K | 21.00K | 0.00 | 4.00K | 2.21K | 4.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -30.00K | -25.00K | -24.00K | -21.00K | -21.00K | 500.00K | -4.00K | -2.21K | -4.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 160.62K | 25.74K | 25.68K | 33.88K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 13.11M | 7.84M | 8.77M | 8.31M | 7.90M | 4.52M | 3.21M | 1.76M | 886.07K | 3.71M | 3.78M | 5.21M | 2.33M | 803.98K | 1.37M | 1.04M | 1.07M | 617.26K | 22.75K | 462.00K |
| General & Administrative | 8.16M | 6.16M | 4.88M | 4.39M | 3.69M | 2.74M | 1.31M | 718.05K | 423.35K | 1.12M | 2.54M | 2.53M | 2.08M | 1.30M | 1.00M | 618.54K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.16M | 6.16M | 4.88M | 4.39M | 3.69M | 2.74M | 1.31M | 718.05K | 423.35K | 1.12M | 2.54M | 2.53M | 2.08M | 1.30M | 1.00M | 618.54K | 1.38M | 192.37K | 177.78K | 168.91K |
| Other Expenses | 0.00 | 353.00K | 82.00K | -205.00K | -856.00K | -68.00K | 6.00K | 221.90K | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.58K | -4.89K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.27M | 14.00M | 13.65M | 12.49M | 10.74M | 6.05M | 4.28M | 2.48M | 1.31M | 4.83M | 7.43M | 10.11M | 6.71M | 3.84M | 2.40M | 1.69M | 2.47M | 812.95K | 228.69K | 637.31K |
| Cost & Expenses | 21.27M | 14.00M | 13.65M | 12.49M | 10.74M | 6.05M | 4.28M | 2.48M | 1.31M | 4.83M | 7.43M | 10.11M | 6.71M | 3.84M | 2.40M | 1.69M | 2.47M | 812.95K | 228.69K | 637.31K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.73K | 1.74K | 10.54K | 14.73K | 41.03K | 51.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.38K | 43.96K | 0.00 | 7.73K | 2.72K | 12.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.60K | 36.59K |
| Depreciation & Amortization | 30.00K | 25.00K | 24.00K | 21.00K | 21.00K | 15.00K | 4.00K | 2.21K | 4.11K | 2.47K | 1.11M | 2.37M | 2.30M | 1.67M | 30.20K | 26.74K | 18.35K | 3.32K | 28.15K | 6.41K |
| EBITDA | -19.31M | -13.98M | -13.62M | -12.24M | -10.60M | -5.64M | -4.26M | -2.15M | -1.50M | -5.01M | -6.51M | -7.70M | -4.51M | -3.32M | -2.27M | -2.34M | -2.29M | -783.89K | -190.26K | -630.30K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,098.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.62% | -3,045.78% | -680.92% | -1,762.12% |
| Operating Income | -21.27M | -14.00M | -13.65M | -12.70M | -11.59M | -6.76M | -4.52M | -2.48M | -1.31M | -4.83M | -7.43M | -10.11M | -6.71M | -3.84M | -2.40M | -1.69M | -2.31M | -787.21K | -203.01K | -603.43K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,352.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,438.05% | -3,058.67% | -790.56% | -1,781.04% |
| Total Other Income/Expenses | 1.93M | 353.00K | 82.00K | 434.00K | 975.00K | 747.00K | 259.00K | 280.63K | -104.38K | -185.41K | -230.99K | 37.57K | -174.26K | -422.84K | 101.28K | -168.32K | 57.19K | -12.38K | 10.28K | 66.55K |
| Income Before Tax | -19.34M | -13.65M | -13.56M | -12.27M | -10.62M | -5.65M | -4.26M | -2.20M | -1.43M | -4.78M | -7.41M | -10.05M | -6.61M | -4.27M | -2.44M | -1.85M | -2.31M | 0.00 | -192.73K | -570.16K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,130.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,440.21% | 0.00% | -750.53% | -1,682.83% |
| Income Tax Expense | 43.00K | 28.00K | 28.00K | 27.00K | 31.00K | 80.00K | -9.00K | 22.31K | 12.45K | 42.28K | 7.73K | 2.72K | 12.57K | 499.08K | 41.69K | 163.43K | 20.20K | -9.19K | 17.87K | 69.86K |
| Net Income | -19.38M | -13.68M | -13.59M | -12.29M | -10.65M | -5.73M | -4.26M | -2.22M | -1.44M | -4.82M | -7.41M | -10.05M | -6.61M | -4.27M | -2.44M | -1.85M | -2.33M | -778.02K | -210.60K | -640.02K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,146.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,452.78% | -3,022.96% | -820.13% | -1,889.02% |
| EPS | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 | -0.47 | -0.40 | -1.55 | -2.71 | -4.11 | -2.93 | -2.98 | -2.54 | -2.04 | -2.91 | -0.89 | -0.50 | -2.35 |
| EPS Diluted | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 | -0.47 | -0.40 | -1.55 | -2.71 | -4.11 | -2.93 | -2.98 | -2.54 | -2.04 | -2.91 | -0.89 | -0.50 | -2.35 |
| Weighted Avg Shares Out | 32.57M | 26.44M | 20.77M | 15.68M | 11.99M | 7.74M | 5.94M | 4.74M | 3.62M | 3.11M | 2.73M | 2.45M | 2.26M | 1.43M | 960.48K | 909.72K | 802.30K | 876.03K | 420.15K | 272.16K |
| Weighted Avg Shares Out (Dil) | 32.57M | 26.44M | 20.77M | 15.68M | 11.99M | 7.74M | 5.94M | 4.74M | 3.62M | 3.11M | 2.73M | 2.45M | 2.26M | 1.43M | 960.48K | 909.72K | 802.30K | 876.03K | 420.15K | 272.16K |
DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation to the Company's lead...
DiaMedica Therapeutics Announces $30 Million Private Placement
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced it has entered into a definitive agreement with ten accredited investors in a private placement of $30...
DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study
DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent stroke.
DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the initiation of the first site for its pivotal ReMEDy2 Trial, a Phase 2/3 clinical study of...
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2021 Results - Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2021 Results - Earnings Call Transcript
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended June 30, 2021. DiaMedica will host a...
DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second quarter 2021 financial results will be released after the markets close on Wednesday, August...
DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second quarter 2021 financial results will be released after the markets close on Wednesday, August...
New Strong Sell Stocks for July 21st
CNO, CLOV, DMAC, HCAT and IMAX have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2021.
Moving Average Crossover Alert: DiaMedica Therapeutics (DMAC)
DiaMedica Therapeutics (DMAC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Source: https://incomestatements.info
Category: Stock Reports